What question did this study set out to answer?

This study aims to assess the fatal toxicity signals associated with antibody-drug conjugates in endometrial cancer.

July 4, 2026ESMO Open0 citationsOpen Access

86P Payload-driven fatal toxicity signals of antibody–drug conjugates in endometrial cancer: A FAERS disproportionality analysis

Key Points

This study aims to assess the fatal toxicity signals associated with antibody-drug conjugates in endometrial cancer.
Disproportionality analysis using the FDA Adverse Event Reporting System (FAERS)
Focused on associations between ADCs and reported fatal toxicities
Analyzed adverse event profiles in patients with endometrial cancer
Identified significant associations between ADCs and fatal toxicities
Highlighted specific adverse events with fatal outcomes
Suggests increased monitoring for endometrial cancer patients receiving ADCs

Abstract

Antibody–drug conjugates (ADCs) have expanded therapeutic options in gynecologic malignancies, including endometrial cancer, but are associated with potentially serious and fatal toxicities. This study evaluates the association between ADCs and adverse event profiles, including fatal outcomes, using the FDA Adverse Event Reporting System.

Ask AI

Helpful

Bookmark

View Full Paper